Every 8-K that Crinetics Pharmaceuticals (CRNX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CRNX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRNX filings page.
Crinetics Pharmaceuticals, Inc. (CRNX) completed its merger with Vertex Pharmaceuticals Incorporated on September 1, 2026. Clark Merger Sub, Inc. merged with and into Crinetics, which now continues as the surviving corporation and a wholly owned subsidiary of Vertex.
At the Effective Time, each issued and outstanding share of Crinetics common stock (with customary exceptions) was canceled and converted into the right to receive $85.00 in cash per share, subject to withholding taxes. Unvested stock options and restricted stock units fully vested; in-the-money options and RSUs were cashed out based on the $85.00 price, while out-of-the-money options were canceled for no consideration. Crinetics’ equity and employee stock plans and its at-the-market Sales Agreement with SVB Leerink LLC and Cantor Fitzgerald & Co. were terminated. Trading in CRNX on Nasdaq was suspended, and Crinetics requested delisting via Form 25, to be followed by Form 15 to terminate registration and suspend reporting obligations. An aggregate of approximately $10.0 billion was paid by Vertex using cash on hand and term loan borrowings. All Crinetics directors and officers resigned at closing and were replaced by Vertex designees, and Crinetics’ certificate of incorporation and bylaws were amended and restated in accordance with the Merger Agreement.
Crinetics Pharmaceuticals, Inc. (CRNX) reported results of its August 28, 2026 special shareholders meeting to vote on its proposed acquisition by Vertex Pharmaceuticals. Of 106,095,205 common shares outstanding and entitled to vote as of July 27, 2026, 79,264,631 shares were represented in person or by proxy, a 74.71% quorum.
Shareholders approved the Merger Proposal to adopt the July 6, 2026 Merger Agreement among Crinetics, Vertex and Clark Merger Sub, Inc., under which Merger Sub will merge with and into Crinetics and Crinetics will become a wholly owned subsidiary of Vertex. Proposal 1 received 79,240,098 votes for, 13,618 against and 10,915 abstentions. An advisory proposal on merger-related executive compensation (Proposal 2) did not receive the requisite support, but is non-binding and not a condition to closing. Proposal 3, an adjournment proposal, was not presented because sufficient votes were obtained for the Merger Proposal. With shareholder approval, the final outstanding condition to closing the Merger is satisfied, and Crinetics anticipates closing on or about September 1, 2026.
Crinetics Pharmaceuticals, Inc. (CRNX) filed an update related to its pending all-cash merger with Vertex Pharmaceuticals, under which Vertex will acquire Crinetics for $85.00 per share, implying an equity value of approximately $10 billion. A special shareholder meeting to vote on the merger is scheduled for August 28, 2026, and the board continues to unanimously recommend voting in favor of the merger and related proposals.
Crinetics disclosed shareholder lawsuits and demand letters alleging deficiencies in the proxy disclosures and stated that it believes these claims are without merit, but is voluntarily providing supplemental disclosures. These include more detail on the board’s process, a pending derivative action over director compensation, and expanded summaries of valuation work by J.P. Morgan and Leerink Partners, such as revenue-based trading multiples, discounted cash flow assumptions, management forecasts through 2045, and advisory fee arrangements. The projections include risk‑adjusted total revenue of $1,057 million in 2030, significant net operating loss carryforwards and net cash, which both advisors used in their fairness analyses when comparing to the $85.00 merger consideration.
Crinetics Pharmaceuticals, Inc. reports further progress toward its planned acquisition by Vertex Pharmaceuticals. The Hart-Scott-Rodino waiting period for the merger expired at 12:45 p.m. Eastern Time on August 12, 2026, and required antitrust approvals in Austria, Germany and Australia have been received, with an Australian waiting period scheduled to expire on August 27, 2026 at 9:59 a.m. Eastern Time.
The merger still depends on remaining closing conditions, including adoption of the merger by Crinetics’ shareholders at a special meeting on August 28, 2026. Assuming shareholder approval, the companies expect the merger and related transactions to close in early September 2026. Crinetics highlights extensive forward‑looking risks and directs shareholders to its definitive proxy statement filed July 31, 2026 for detailed information.
Crinetics Pharmaceuticals agreed to be acquired by Vertex Pharmaceuticals for $85.00 per share in cash, implying a total equity value of about $10.0 billion, or $8.8 billion net of estimated cash acquired. Closing is anticipated in the third quarter of 2026, subject to regulatory approvals and approval by Crinetics stockholders.
For the quarter ended June 30, 2026, Crinetics reported $25.1 million in revenue, up from $1.0 million a year earlier, including $24.0 million in net product revenue from PALSONIFY. Net loss was $120.9 million, or $1.14 per share. Cash, cash equivalents and investment securities totaled $1.2 billion at June 30, 2026.
The company highlighted PALSONIFY commercial uptake, with 245 enrollment forms in the quarter, 385 unique prescribers within the first three quarters of launch, and over 70% of treated patients on reimbursed therapy. Crinetics also received U.S. FDA Rare Pediatric Disease Designation for atumelnant in classic congenital adrenal hyperplasia.
Crinetics Pharmaceuticals, Inc. describes new Non-Compete Agreements entered into on July 6, 2026 with key employees in connection with its previously announced Merger Agreement with Vertex Pharmaceuticals Incorporated. The merger will combine Crinetics with a wholly owned Vertex subsidiary, with Crinetics surviving as a wholly owned subsidiary of Vertex.
Under these Non-Compete Agreements, Crinetics’ President and CEO R. Scott Struthers, CFO Tobin Schilke, Chief Scientific Officer Stephen Betz, and Chief Commercial Officer Isabel Kalofonos agree that for one year immediately following the merger closing date they will not perform services in any capacity for specified restricted businesses in territories where Crinetics conducts business as of closing. In consideration for these commitments, on the merger closing date Mr. Schilke, Dr. Betz and Ms. Kalofonos will receive cash payments of $140,000, $30,000 and $30,000, respectively.
The report also includes extensive forward-looking statement disclosures and outlines that Crinetics plans to file preliminary and definitive proxy statements so its stockholders can vote on approval of the proposed transaction with Vertex.
Crinetics Pharmaceuticals agreed to be acquired by Vertex Pharmaceuticals in an all-cash merger. Crinetics stockholders will receive $85.00 per share in cash, implying a total equity value of approximately $10.0 billion, or about $8.8 billion net of estimated cash acquired.
At closing, Crinetics will become a wholly owned Vertex subsidiary. All unvested Crinetics stock options and restricted stock units will fully vest, with in-the-money awards converted into cash based on the $85.00 price; underwater options will be canceled. The deal is expected to close in the third quarter of 2026, subject to Crinetics stockholder approval, antitrust and other regulatory clearances, and customary closing conditions, and is not subject to a financing condition.
Crinetics Pharmaceuticals, Inc. reported the results of its annual stockholder meeting held via live webcast on June 18, 2026. Holders of 102,030,415 shares of common stock were present virtually or by proxy, representing approximately 97% of the outstanding shares eligible to vote.
Stockholders elected three Class II directors—Caren Deardorf, Weston Nichols, Ph.D., and Stephanie S. Okey, M.S.—to three-year terms expiring at the 2029 annual meeting. They also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved, on an advisory basis, the compensation of the company’s named executive officers.
Crinetics Pharmaceuticals reported first-quarter 2026 revenue of $10.7 million, driven by $10.3 million in net product revenue from the U.S. launch of PALSONIFY for acromegaly. Management highlighted strong prescriber uptake, with 232 enrollment forms and 263 unique healthcare providers within the first two quarters of launch, and about 70% of patients on reimbursed therapy.
R&D expenses rose to $100.1 million and selling, general and administrative costs to $50.8 million, reflecting expansion as a commercial-stage company. Net loss widened to $127.8 million. Cash, cash equivalents and investment securities were $1.3 billion, supported by $380 million of net proceeds from a January 2026 equity offering. The company reaffirmed 2026 GAAP operating expense guidance of $600–650 million and non-GAAP operating expense guidance of $480–520 million, and outlined progress on its global PALSONIFY strategy and late-stage pipeline including atumelnant.
Crinetics Pharmaceuticals, Inc. reports that Jeff Knight’s previously disclosed resignation as Chief Development and Operating Officer became effective on April 10, 2026. On that date, the company and Mr. Knight entered into an Independent Consultant Agreement covering operational and clinical development services.
The consulting term runs from April 10, 2026 to April 10, 2027, with an option to renew for six months if both sides agree in writing. Mr. Knight will be paid $400 per hour, up to 20 hours per month, plus reimbursement of reasonable pre-approved expenses. His unvested restricted stock units and stock options are forfeited on the resignation date, while vested options remain exercisable for three months after the consulting period ends or earlier termination for cause. He also provides a general release of claims, and the company extends certain indemnification rights during the consulting term.
Crinetics Pharmaceuticals announced that Jeff Knight has decided to resign as Chief Development and Operating Officer, effective on or about April 10, 2026. The company states that he is leaving to pursue another opportunity and that his resignation is not due to any disagreement over operations, policies, or practices.
Crinetics plans to reassign all of Mr. Knight’s managerial responsibilities and direct reports to other members of its executive leadership team, signaling a redistribution of his duties rather than the creation of a new replacement role at this time.
Crinetics Pharmaceuticals reported a change in its independent auditor. The Audit Committee dismissed BDO USA, P.C. as the company’s independent registered public accounting firm and stated that BDO’s reports on the 2024 and 2025 financial statements contained no adverse or qualified opinions.
The company reported no disagreements with BDO and no reportable events during those periods. The Audit Committee appointed PricewaterhouseCoopers LLP (PwC) as the new independent registered public accounting firm for the fiscal year ending December 31, 2026. BDO’s confirming letter to the SEC is filed as an exhibit.
Crinetics Pharmaceuticals reported fourth quarter and full year 2025 results marked by the U.S. launch of PALSONIFY for acromegaly and its first product revenue. Fourth quarter revenue was $6.2 million, including $5.4 million in net product revenue from PALSONIFY, with more than 200 enrollment forms and over 125 prescribing healthcare providers in the quarter.
For 2025, total revenue was $7.7 million, while research and development expenses reached $332.1 million and selling, general and administrative expenses were $191.3 million, leading to a net loss of $465.3 million. The company used $326.2 million of cash, below prior guidance, and ended 2025 with $1.0 billion in cash, cash equivalents and investment securities, rising to about $1.4 billion after a January 2026 equity offering that raised approximately $380 million in net proceeds.
Crinetics highlighted significant pipeline progress, including FDA approval of PALSONIFY in September 2025, a positive CHMP opinion in Europe, multiple pivotal trials for paltusotine and atumelnant, and the first clinical candidate from its nonpeptide drug conjugate platform. For 2026, the company guides to GAAP operating expenses of $600–650 million and non-GAAP operating expenses of $480–520 million, reflecting continued investment in commercialization and late-stage development.
Crinetics Pharmaceuticals, Inc. reported a leadership title change for one of its senior executives. Effective January 2, 2026, Jeff Knight’s role was updated from Chief Operating Officer to Chief Development and Operating Officer. The board of directors approved this change on January 20, 2026, to better reflect his existing responsibilities and scope of duties.
The company stated that there were no changes to Mr. Knight’s compensation arrangements in connection with this new title. Crinetics also confirmed that there are no arrangements or understandings with any other person related to his selection for this role, no family relationships with any director or executive officer, and no reportable related party transactions involving him. His business experience is described in the company’s 2025 proxy statement, which is incorporated by reference.
Crinetics Pharmaceuticals reported preliminary and unaudited fourth-quarter 2025 net product revenue from PALSONIFY (paltusotine) of over $5.0 million for the three months ended December 31, 2025. This early revenue snapshot reflects sales of its commercial product but may change once full year-end financial closing procedures, management review and internal control processes are completed.
The company also provided a business update at the 44th annual J.P. Morgan Healthcare Conference, using a corporate slide deck furnished as an exhibit. All of this information is being furnished rather than filed under securities laws, and Crinetics emphasized that forward-looking statements about its products, development timelines, market potential and cash runway are subject to significant risks and uncertainties.
Crinetics Pharmaceuticals, Inc. entered into an underwriting agreement to issue and sell 7,620,000 shares of its common stock at a public offering price of $45.95 per share, with underwriters purchasing at $43.42275 per share. The company also granted the underwriters a 30-day option to buy up to 1,143,000 additional shares.
The company expects net proceeds of approximately $330.2 million from the offering, or approximately $379.8 million if the option is exercised in full, after underwriting discounts, commissions and estimated expenses. The offering, made under an effective shelf registration statement on Form S-3ASR, is expected to close on January 8, 2026, subject to customary closing conditions.
Crinetics Pharmaceuticals, Inc. reported that Dana Pizzuti, M.D. will step down as Chief Medical and Development Officer effective December 31, 2025. Under a Transition and Separation Agreement, she will serve as a Strategic Regulatory and Development Advisor from January 1, 2026 through up to March 31, 2026. She will receive $577,000 in cash severance, eligibility for a 2025 annual bonus and a prorated 2026 bonus, up to $15,000 of legal fee reimbursement, up to 12 months of COBRA premium reimbursements, and up to $6,500 for a board training course.
Crinetics and Dr. Pizzuti also entered into an Advisor Agreement under which she will provide 10–20 hours per month of services from April 1, 2026 through up to March 30, 2028 for $600 per hour plus expense reimbursement. Certain existing equity awards will continue to vest during this advisory period, with additional vesting protections upon a Change in Control if specified conditions are met. Vested stock options may remain exercisable for up to three years after advisory service ends, subject to a ten-year maximum term.
Crinetics Pharmaceuticals submitted a current report to note that it has released financial results for the period ended September 30, 2025. The company issued a press release on November 6, 2025 summarizing its operations and financial condition for that period, and that release is included as an exhibit to this report. The company also clarifies that the information in this report and the attached press release is being furnished rather than filed, which limits how it is treated under certain securities law liability provisions.
Crinetics Pharmaceuticals announced that the U.S. Food and Drug Administration approved PALSONIFY™ (paltusotine) on September 25, 2025 for the first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. PALSONIFY is described as a selectively-targeted somatostatin receptor type 2 nonpeptide agonist and is now the first once-daily, oral treatment approved for adults with acromegaly. Crinetics is also holding an investor conference call on September 25, 2025 to discuss the approval, and a press release and call replay will be available in the investors section of its website.
Crinetics Pharmaceuticals (Nasdaq:CRNX) furnished an 8-K covering its June 26 2025 R&D Day. Management unveiled new pre-clinical data on three assets—TSHR antagonist CRN12755 for Graves’ disease, SST3 agonist CRN10329 for ADPKD and drug-conjugate CRN09682 for SST2-positive tumors—and outlined the Phase 1/2 BRAVESST2 design enrolling up to 150 patients. Highlights include reductions in thyroid hormone, hyaluronic acid, IL-6 and cystic indices, plus dose-dependent anti-tumor activity. No financial results or guidance were provided; information is “furnished,” not “filed,” and forward-looking statements stress clinical, regulatory and financing risks.